[1] Xiao S, Shi F, Song H, Cui J, Zheng D, Zhang H, Tan K, Wu J, Chen X, Wu J, Tang Y, Dai Y, Lu M#: Characterization of the generic mutant p53-rescue compounds in a broad range of assays. Cancer Cell 2024, accepted.


[2] Song H, Wu J, Tang Y, Dai Y, Xiang X, Li Y, Wu L, Wu J, Liang Y, Xing Y, Yan N, Li Y, Wang Z, Xiao S, Li J, Zheng D, Chen X, Fang H, Ye C, Ma Y, Wu Y, Wu W, Li J, Zhang S, Lu M#. Science Translational Medicine 2023, 15:eabn9155.


[3] Chen S, Wu J, Liang Y, Tang Y, Song H, Wu L, Xing Y, Yan N, Li Y, Wang Z, Xiao S, Lu X, Chen S,Lu M#. Cancer Cell 2021;39(2):225-239.e8.

[4] Tang Y, Song H, Wang Z, Xiao S, Xiang X, Zhan H, Wu L, Wu J, Xing Y, Tan Y, Liang Y, Yan N, Li Y, Li J, Wu J, Zheng D, Jia Y, Chen Z, Li Y, Zhang Q, Zhang J, Zeng H, Tao W, Liu F, Wu Y, Lu M#. Cell Reports 2022;39(2):110622.


[5] Liang Y, An Q, Song H, Tang Y, Xiao S, Wu J, Yan N, Yu B, Cao X, Lu M#: AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity. Journal of Medicinal Chemistry 2023, 66:16579-96.


[6] Wang Z, Zhao Y, Wang Q, Xing Y, Feng L, Kong J, Peng C, Zhang L, Yang H, Lu M#. Signal Transduction and Targeted Therapy 2021;6(1):214.

[7] Yan N, Li Y, Xing Y, Wu J, Li J, Liang Y, Tang Y, Wang Z, Song H, Wang H, Xiao S, Lu M#. EMBO Rep 2022;23(6):e54147.


[8] Lu M, Zak J, Chen S, Sanchez-Pulido L, Severson DT, Endicott J, Ponting CP, Schofield CJ, Lu X#: A code for RanGDP binding in ankyrin repeats defines a nuclear import pathway. Cell 2014, 157:1130-45.


[9] Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X#: Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 2013, 23:618-33.


[10] Lu M, Muers MR, Lu X#: Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding. Nature Reviews Molecular Cell Biology 2016, 17:523-32.

[1] Xiao S*, Shi F*, Song H*, Cui J*...Dai Y#, Lu M#.Cancer Cell 2024, accepted.
[2] Song H*, Wu J*, Tang Y*, Dai Y* ... Lu M#. Science Translational Medicine 2023, 15:eabn9155.
[3] Chen S*, Wu J*, Liang Y* ... Lu X#, Chen S#, Lu M#. Cancer Cell 2021;39(2):225-239.e8.
[4] Tang Y*, Song H*, Wang Z*, Xiao S* ... Liu F#, Wu Y#, Lu M#. Cell Reports 2022;39(2):110622.
[5]Liang Y*, An Q*, Song H*, Tang Y*...Lu M#. Journal of Medicinal Chemistry 2023, 66:16579-96.
[6] Wang Z*, Zhao Y*, Wang Q*, Xing Y* ... Zhang L#, Yang H#, Lu M#.Signal Transduction and Targeted Therapy 2021;6(1):214.
[7] Yan N*, Li Y*... Lu M#. EMBO Rep 2022;23(6):e54147.
[6]Yan Q*, Sun R*, Cui Z*... Lu M#, Zhu Y#, Fan C#. (2022). Nano Today 2022;47:101649.
[7]Wu J*, Li Y*, Wu J*...Lu M#. Clin Transl Med 2021;11(11):e593.
[8] Lu M ...Lu X#. Cell 2014, 157:1130-45
[9] Lu M ...Lu X#. Cancer Cell 2013, 23:618-33.
[10] Lu M ...Lu X#. Nat Rev Mol Cell Biol 2016, 17:523-32

1、Lu, Min; Wu, Jiale; Song, Huaxin. PANDA as a novel therapeutic, PCT/CN2018/085190. The patent has entered China (2020071600684380), US (16959906), EU (EP18898022.1), JP (3148-PCT-JP), AU (2018399726), and CA(0146523-00002).

2、Lu, Min; Wu, Jiale; Song, Huaxin. mp53 rescue compounds and methods of treating a p53 disorder, PCT/CN2019/070117. The patent has entered China (2020071600808010), US(16959894), EU (EP19736093.6), JP (3147-PCT-JP), AU (2019205062), and CA(0146523-00001).

3、Lu, Min; Liang, Ying; Xiao, Shujun; Song, Huaxin. Dual-specificity p53 rescue compound and method of use. 202110659536.4.

4、Lu, Min; Song, Huaxin. A method to screen p53-mutant cancer patients that are applicable for the p53 rescue drugs. 202110659578.8.

5、Lu, Xin; Lu, Min. iASPP phosphorylation and metastatic potential. WIPO, WO 2013/131019 A1

1、Arsenic Trioxide in Refractory Solid Tumors with Rescuable p53 Mutation (https://www.clinicaltrials.gov/ct2/show/NCT04869475)

2、Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS。(https://www.clinicaltrials.gov/ct2/show/NCT03855371)

3、Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations (https://www.clinicaltrials.gov/ct2/show/NCT04906031)

4、Introduction in TP53 Trust (http://tp53.co.uk/interview-with-min-lu/)

5、Introduction in AntiCancer Fund (https://www.anticancerfund.org/en/blog/latest-news-about-drug-repurposing-oncology-4)